All Stories

  1. The direct and indirect effects of vancomycin-resistant enterococci colonization in liver transplant candidates and recipients
  2. Home Exercise Training Improves Exercise Capacity in Cirrhosis Patients: Role of Exercise Adherence
  3. Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis
  4. Soft and hard endpoints in acute variceal bleeding
  5. Eight Weeks of Exercise Training Increases Aerobic Capacity and Muscle Mass and Reduces Fatigue in Patients With Cirrhosis
  6. A Histologic Scoring System for Prognosis of Patients With Alcoholic Hepatitis
  7. A prospective observational study on tolerance and satisfaction to hepatic haemodynamic procedures
  8. A MELD-Based Model to Determine Risk of Mortality Among Patients With Acute Variceal Bleeding
  9. Lack of Correlation Between Preoperative and Intraoperative Liver Hemodynamics
  10. Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study
  11. Reliability of the estimation of total hepatic blood flow by Doppler ultrasound in patients with cirrhotic portal hypertension
  12. Impact of obesity and insulin-resistance on cirrhosis and portal hypertension
  13. Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis
  14. Impact of deep sedation on the accuracy of hepatic and portal venous pressure measurements in patients with cirrhosis
  15. Simvastatin maintains function and viability of steatotic rat livers procured for transplantation
  16. Problemas frecuentes en el diagnóstico y tratamiento de la enfermedad de Wilson
  17. Good long-term outcome of Budd-Chiari syndrome with a step-wise management
  18. Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: A case-control study
  19. Effect of Meal Ingestion on Liver Stiffness in Patients with Cirrhosis and Portal Hypertension
  20. Metabolomics Discloses Potential Biomarkers for the Noninvasive Diagnosis of Idiopathic Portal Hypertension
  21. Spleen stiffness: Toward a noninvasive portal sphygmomanometer?
  22. Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction
  23. Use of early-TIPS for high-risk variceal bleeding: Results of a post-RCT surveillance study
  24. Elastography, Spleen Size, and Platelet Count Identify Portal Hypertension in Patients With Compensated Cirrhosis
  25. Guías de práctica clínica en gastroenterología y hepatología. Una herramienta insuficientemente utilizada por la Asociación Española para el Estudio del Hígado y la Asociación Española de Gastroenterología
  26. Cardiovascular Risk Factors and Systemic Endothelial Function in Patients With Cirrhosis
  27. Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension
  28. Asignación de factor de impacto a la revista Gastroenterología y Hepatología
  29. Bone morphogenetic protein receptor 2 in patients with idiopathic portal hypertension
  30. Diagnosing and monitoring cirrhosis: Liver biopsy, hepatic venous pressure gradient and elastography
  31. Postprandial effects of dark chocolate on portal hypertension in patients with cirrhosis: results of a phase 2, double-blind, randomized controlled trial
  32. Efficacy and Safety of Anticoagulation on Patients With Cirrhosis and Portal Vein Thrombosis
  33. Patients Whose First Episode of Bleeding Occurs While Taking a β-Blocker Have High Long-term Risks of Rebleeding and Death
  34. Hipertensión portal: recomendaciones para su evaluación y tratamiento
  35. Intestinal and plasma VEGF levels in cirrhosis: the role of portal pressure
  36. Insulin resistance in patients with cirrhosis and portal hypertension
  37. Sinusoidal Endothelial Dysfunction Precedes Inflammation and Fibrosis in a Model of NAFLD
  38. Acute Variceal Bleeding
  39. Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation
  40. Hypercoagulability in Patients With Chronic Noncirrhotic Portal Vein Thrombosis
  41. Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors
  42. Insulin resistance and liver microcirculation in a rat model of early NAFLD
  43. Evaluation of regional hepatic perfusion (RHP) by contrast-enhanced ultrasound in patients with cirrhosis
  44. Complications after ERCP in liver transplant recipients
  45. The Amount of Alcohol Consumption Negatively Impacts Short-Term Mortality in Mexican Patients With Alcoholic Hepatitis
  46. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension
  47. Portal cholangiopathy: radiological classification and natural history
  48. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis
  49. Characterization of γδ T cell subsets in organ transplantation
  50. Hepatic endothelial dysfunction and abnormal angiogenesis: New targets in the treatment of portal hypertension
  51. A Specialized, Nurse-Run Titration Clinic: A Feasible Option for Optimizing β-Blockade in Non–Clinical Trial Patients
  52. Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension
  53. Renin–angiotensin–aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysis
  54. Early Use of TIPS in Patients with Cirrhosis and Variceal Bleeding
  55. Ultrasonographic evaluation of liver surface and transient elastography in clinically doubtful cirrhosis
  56. Developments and controversies in the management of oesophageal and gastric varices
  57. Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: A clinical-hemodynamic correlation study
  58. Acute and long-term effects of inhaled iloprost in portopulmonary hypertension
  59. Extrahepatic portal vein thrombosis in children and adolescents: Influence of genetic thrombophilic disorders
  60. An uncommon cause of massive scrotal enlargement
  61. The clinical use of HVPG measurements in chronic liver disease
  62. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension
  63. Idiopathic Portal Hypertension in Patients With HIV Infection Treated With Highly Active Antiretroviral Therapy
  64. Simvastatin Lowers Portal Pressure in Patients With Cirrhosis and Portal Hypertension: A Randomized Controlled Trial
  65. Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver
  66. Portal Hypertension–Related Complications After Acute Portal Vein Thrombosis: Impact of Early Anticoagulation
  67. A New Scoring System for Prognostic Stratification of Patients With Alcoholic Hepatitis
  68. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis
  69. Noninvasive Prediction of Clinically Significant Portal Hypertension and Esophageal Varices in Patients With Compensated Liver Cirrhosis
  70. Large-conductance calcium-activated potassium channels modulate vascular tone in experimental cirrhosis
  71. Portal Hypertension and Gastrointestinal Bleeding
  72. Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy
  73. The management of portal hypertension: Rational basis, available treatments and future options
  74. The Treatment of Acute Variceal Bleeding
  75. Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study
  76. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats
  77. Decreased intrahepatic response to ?1-adrenergic agonists in lipopolysaccharide-treated rats is located in the sinusoidal area and depends on Kupffer cell function
  78. Measurement of Portal Pressure and Its Role in the Management of Chronic Liver Disease
  79. Effects of propranolol on venous compliance in conscious rats with pre-hepatic portal hypertension
  80. Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers
  81. Pharmacological Reduction of Portal Pressure and Long-Term Risk of First Variceal Bleeding in Patients with Cirrhosis
  82. Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension
  83. Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state
  84. Utility of Color Doppler Ultrasonography Predicting TIPS Dysfunction
  85. The Management of Portal Hypertension
  86. Portal Hypertension Secondary to Myelofibrosis: A Study of Three Cases
  87. Portal Hypertension
  88. Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd-Chiari syndrome
  89. Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis
  90. Variceal Bleeding: Pharmacological Therapy
  91. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: A randomized, double-blind trial
  92. Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis
  93. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis
  94. Improved clinical outcome using polytetrafluoroethylene-coated stents for tips: Results of a randomized study
  95. Increased CD11b neutrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera
  96. Management of gastrointestinal bleeding in patients with cirrhosis of the liver
  97. Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers
  98. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis
  99. Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis
  100. Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers
  101. Current management of portal hypertension
  102. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis
  103. Novel approaches to treat portal hypertension
  104. Somatostatin and analogues in portal hypertension
  105. Stenosis of the suprahepatic inferior vena cava as a complication of transjugular intrahepatic portosystemic shunt in Budd-Chiari patients
  106. Selective arterial embolization for life threatening hemobilia after transjugular intrahepatic portosystemic shunt placement
  107. Persistent hypertransaminasemia as the presenting feature of celiac disease